Sean Patrick Multidisciplinary Collaborative Grant
The HERA Women’s Cancer Foundation provides funds for a project focused on the cause, early detection, treatment, and/or understanding of ovarian cancer. This annual award provides $50,000 for a cross-disciplinary project that is collaborative in nature. The application must identify two (or more) scientists with different yet complementary skills and explain how these skills will be synergistic in addressing the ovarian cancer problem. Applications are now being accepted for the 2013 award.
Read about the 2012 Sean Patrick Multidisciplinary Collaborative Grant recipients here.
Sean Patrick, for whom this grant was named, was a champion for innovative ovarian cancer research. She was frustrated by the disproportionate amount of government funds that went to other cancers and that the traditional chemotherapies had not changed the prognosis of ovarian cancer in decades. To change this convention, she founded the HERA Women’s Cancer Foundation whose mission is to stop the loss of women from ovarian cancer by promoting Health, Empowerment, Research, and Awareness. Sean believed that the therapies with the most potential would be formulated by combining great ideas from different labs and possibly different fields. This grant is in honor of her vision and aims to give scientists the opportunity to put their heads together and test ideas that may not be fundable by other agencies.
Applications and questions should be directed to Meg Steitz, HERA’s Executive Director, firstname.lastname@example.org, or (970) 948-7360.
HERA funds other science grants to encourage “outside the box” ideas regarding the research of new directions in the treatment, early detection and prevention of ovarian cancer. Click here to read HERA’s priorities when funding scientific research grants.
Scientists and clinicians of non-profit research, medical service, and educational institutions located in the U.S. are eligible and encouraged to apply.
Applications are due June 3, 2013. The applications will be peer reviewed. The recipients will be notified in August. The full application includes one pdf file with the following:
- One or two completed and signed cover pages; see link to the application below. If the research proposed is performed in two different labs, please submit a face page for each lab. If your application is chosen to receive the award, HERA will send the amount indicated in the budget (totaling $50K) to the respective labs/institutions.
- Include a half-page executive summary of the project that is clear to patients, donors, and scientists.
- Project plan (3 pages): Use 12-point font and 1-inch margins. The project plan should clearly describe the contribution of each collaborator and the objectives, hypothesis, rationale, relevant preliminary results, methods, and expected results of the project. Explain how each collaborator’s skills will be synergistic in addressing the ovarian cancer problem. Explain how the collaboration is new and, if scientists are at different institutions, how they will work together on the project. The literature cited does not have to fit in the three-page limit. The application with the most innovative ideas, that have translational potential, and that develop collaborative interactions will be favorably reviewed.
- Detailed budget and budget justification: Funds will only cover direct costs of the project: reagents and supplies, justifiable expenses, and up to $25K may cover salary support. Indirect costs are not covered by this award as stated in the HERA By-laws.
- Include an updated NIH-style biosketch for both PIs with personal statements (include unique cross-disciplinary strengths) and current and pending support sections (describe overlap or distinction with current application).
- Other factors and assurances: If the proposed work involves human subjects, vertebrate animals, or recombinant DNA research, the PI and Institutional Official must certify that they will adhere to appropriate regulations of the United States Public Health Service, National Institute of Health, including approval of the study by a properly constituted Institutional Review Board, Institutional Animal Care and Use Committee, or Biosafety Committee, respectively.
An electronic copy in a single PDF file of the complete application should be emailed to: email@example.com.
If you receive this award:
The HERA Women’s Cancer Foundation will contact you regarding information about your proposal and research for its website, or HERA may use the executive summary with your approval. HERA may also ask you to participate in an interview that will be posted on HERA’s website.
- All publications, abstracts, or similar communications resulting from work supported by the HERA Women’s Cancer Foundation must acknowledge this support. A PDF of the publication and/or abstract must be sent to the HERA Foundation.
- A mid-grant progress report that describes the progress of the research and is clear to a general audience is due February 1.
- A final report that describes the results of the study and is clear to a general audience, should be submitted to HERA within 90-days of project completion. If the funds are not used in the first year, please contact HERA and a no-cost extension will be approved.
- After the completion of the project, we request your assistance on HERA’s Scientific Advisory Board for 2 years. These duties include reviewing short grants (like this one) two times per year.